Approved indications: Trulance immediate release is indicated in adults for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C).

Off-label uses: Clinically meaningful off-label uses are not well established; most published studies and guideline discussions focus on the approved indications of CIC and IBS-C, so routine prescribing outside these conditions is uncommon.

Efficacy expectations (CIC): In 12-week trials for CIC, about 20–21% of adults on plecanatide 3 mg once daily were durable responders (regular complete spontaneous bowel movements) compared with about 10–13% on placebo, with improvements in stool frequency and consistency often beginning in the first week and some patients having a bowel movement within 24 hours of the first dose.

Efficacy expectations (IBS-C): In IBS-C, roughly 30% of patients achieved combined improvement in abdominal pain and bowel movements versus about 18% on placebo over 12 weeks, with symptom relief (stool frequency, pain, bloating) typically emerging within the first few weeks and maintained during treatment.

Comparison to similar drugs: As a guanylate cyclase-C agonist, plecanatide offers efficacy comparable to other prescription secretagogues (such as linaclotide and lubiprostone) and is strongly recommended with high-quality evidence in guidelines for IBS-C, with the advantage of minimal systemic absorption and a relatively low discontinuation rate due to side effects.

Typical dosing by condition and age: For adults with either chronic idiopathic constipation or IBS-C, the standard dose is 3 mg taken orally once daily; Trulance is contraindicated in children under 6 years and should generally be avoided in those 6 to less than 18 years because safety and effectiveness are not established.

How and when to take it: Take one tablet by mouth once a day, at any time of day, with or without food, swallowing the tablet whole; adults who cannot swallow tablets may crush a tablet and take it immediately in 1 teaspoon of room-temperature applesauce, disperse it in 30 mL of water to drink right away, or give the water mixture through a nasogastric or gastric feeding tube as directed.

Special dosing instructions and precautions: Use Trulance regularly each day rather than only as needed, and do not use it at all if a doctor has told you that you have a bowel blockage; no dose adjustments are generally required for kidney or liver problems, but patients who are frail, elderly, or at risk of dehydration should be monitored for diarrhea and fluid loss.

Missed dose guidance: If you miss a dose, skip the missed dose and take your next dose at the usual time; do not take two doses at once to make up for a missed dose.

Overdose: Serious toxicity is not expected with modest overdose because systemic absorption is minimal, but taking more than prescribed may increase diarrhea and dehydration risk, so you should contact your prescriber, call a poison control center, or seek emergency care if a large overdose or severe symptoms occur.

Common side effects: The most common side effect is diarrhea (about 4–5% of treated adults), sometimes severe but usually mild to moderate; it often begins within the first month (sometimes within the first few days), and other less frequent effects include gas, bloating, abdominal discomfort, nausea, dizziness, and upper respiratory symptoms.

Serious or rare adverse effects: Severe diarrhea can lead to dehydration, dizziness, weakness, or reduced urination and requires stopping the drug and prompt medical attention; as with most medications, rare serious allergic reactions (rash, swelling of face or throat, trouble breathing) are possible and warrant emergency care.

Warnings and age limits: Trulance carries a boxed warning for risk of serious dehydration in children, is contraindicated in patients younger than 6 years and in anyone with known or suspected mechanical gastrointestinal obstruction, and its use should be avoided in patients 6 to less than 18 years because safety and effectiveness are not established.

Pregnancy, breastfeeding, and organ impairment: Plecanatide and its active metabolite are negligibly absorbed from the gut, so maternal use is not expected to result in clinically relevant exposure to the fetus or breastfed infant, but human pregnancy data are limited and decisions should be individualized; no specific dose adjustments are recommended for kidney or liver impairment, though any patient prone to dehydration should be monitored carefully.

Overall safety profile: Because it acts locally in the intestine with minimal systemic absorption, Trulance has few systemic side effects and a low rate of treatment discontinuation (around 4% overall, about 2% due to diarrhea), making its safety profile favorable compared with many other chronic constipation therapies.

Reporting and safety updates: Side effects can be reported to the FDA MedWatch program (1-800-FDA-1088 or the MedWatch website) or to the manufacturer’s product information line; current prescribing information and safety communications are updated regularly on FDA and manufacturer websites.

Drug and supplement interactions: Plecanatide is minimally absorbed, does not significantly involve common liver enzymes or drug transporters, and has no known clinically important drug–drug interactions, but you should still tell your clinician about all prescription medicines, over-the-counter products, and herbal supplements you use.

Food, alcohol, and other products: Trulance may be taken with or without food; high-fat meals can make stools looser in some people, and alcohol or other drugs that promote fluid loss (for example, strong diuretics or other laxatives) may increase the risk of dehydration if diarrhea occurs.

Key precautions and when use may be unsafe: Do not use Trulance if you have a known or suspected mechanical gastrointestinal obstruction, and avoid it in anyone under 18 years (especially children under 6 years, in whom it is contraindicated) because of the risk of serious dehydration; use extra caution in patients who are frail, have low blood pressure, or have conditions where fluid loss could be dangerous.

Monitoring needs: Routine blood tests or ECGs are not usually required, but patients should be monitored clinically for new or worsening diarrhea, lightheadedness, or decreased urination, and those who develop severe diarrhea may need assessment of hydration and electrolytes.

Q: What is Trulance immediate release used for?
A: It is a once-daily oral medicine for adults that treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) by helping your bowels move more regularly and comfortably.

Q: How long does it take for Trulance to start working?
A: Some people have a bowel movement within the first day, many notice improvement in stool frequency and ease of passage in the first week, and benefits are generally maintained over the 12-week trial periods when the drug is taken every day.

Q: When should I take Trulance, and do I need to take it with food?
A: You can take Trulance once a day at any convenient time, with or without food, but it is best to take it at about the same time each day so you do not forget doses.

Q: What if I get diarrhea while taking Trulance?
A: Mild diarrhea is common and often short-lived, but if diarrhea is severe, causes dizziness or decreased urination, or does not improve, you should stop the medication, drink fluids, and contact your healthcare provider right away.

Q: Can children or teenagers take Trulance?
A: No—Trulance is only for adults; it is contraindicated in children younger than 6 years because of the risk of serious dehydration, and its use should be avoided in those 6 to less than 18 years since safety and effectiveness are not established.

Q: Is Trulance safe during pregnancy or while breastfeeding?
A: Because the drug stays in the gut and is minimally absorbed, fetal or infant exposure is expected to be very low, but human data are limited, so you should discuss with your clinician whether the benefits of treatment outweigh any potential but likely small risks in your situation.

Storage: Store Trulance at room temperature (68°F to 77°F / 20°C to 25°C), protect it from moisture, and keep the tablets in the original bottle or blister pack until use; keep out of reach of children.

Disposal: Safely throw away Trulance that is expired or no longer needed, ideally through a local medicine take-back program or following pharmacist or community guidance; do not share it with others.